MANCHESTER, England, July 11, 2016 /PRNewswire/ --
F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ralf Schmid to the position of Chief Financial Officer, effective from 4th July 2016. Ralf brings over 20 years' experience to F2G, with considerable expertise in M&A, licensing, public and private market transactions.
Ralf Schmid joins F2G from Nabriva Theraputics AG (NASDAQ: NBRV), where he served on the management board since the company's inception in 2006. In his role as Chief Financial and Chief Operating Officer, Ralf was instrumental in taking the company public on NASDAQ in September 2015. He has held various senior positions in finance and administration at several multi-national companies including Sandoz where he led the spin-off of Nabriva. Ralf holds a Master's degree in finance and economics from Otto-Friedrich-Universität Bamberg, Germany.
Ian Nicholson, CEO of F2G, commented, "Following our successful $60 million financing, I am delighted to welcome Ralf to the F2G team. His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success."
Ralf Schmid added, "I am very pleased to be joining F2G at this pivotal stage as the company transitions its lead programme into Phase II development and onto the market. I look forward to working with the highly experienced board and dynamic team at the company as we progress the pipeline."
About F2G Ltd: F2G is a world leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management & board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides are active against Aspergillus and other rare and resistant moulds and act via a completely different mechanism than currently marketed antifungal agents. Due to their new mechanism of action, orotomides are active against fungal infections resistant to current therapies, a growing problem globally. A small PK Phase 2 clinical trial for F901318 is planned for 2H 2016 with pivotal registration trials in Invasive Aspergillosis planned for 1H 2017 based on an accelerated regulatory pathway agreed with the relevant agencies. F901318 is being developed both as IV and oral formulations and promises to have a safe and well-tolerated profile. The company recently announced a $60 million financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections.
SOURCE F2G Ltd.